{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:34:59Z","timestamp":1792175699461,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Oasmia Pharmaceutical AB"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ygyno.2019.11.034","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T03:51:34Z","timestamp":1575863494000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel"],"prefix":"10.1016","volume":"156","author":[{"given":"I.","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bergfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Franquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Lisyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bjermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Heldring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.11.034_bb0005","article-title":"SEMINA-2014-Ovarian cancer","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0015","unstructured":"NCCN Clinical Practice Guidelines in Oncology Version 3.2017 (2017)"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejogrb.2017.04.016","article-title":"British Gynaecological Cancer Society (BGCS) epithelial ovarian\/fallopian tube\/primary peritoneal cancer guidelines: recommendations for practice","author":"Fotopoulou","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy285.142","article-title":"933OCarboplatin\/pegylated liposomal doxorubicin\/bevacizumab (CD-BEV) vs. carboplatin\/gemcitabine\/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: a prospective randomized phase III ENGOT\/GCIG-intergroup study (AGO study group, AGO-Austria)","author":"Pfisterer","year":"2018","journal-title":"Ann. Oncol., Munich"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0035","doi-asserted-by":"crossref","unstructured":"E. Pujade-Lauraine, J.A. Ledermann, F. Selle, V. Gebski, R.T. Penson, A.M. Oza, J. Korach, T. Huzarski, A. Poveda, S. Pignata, M. Friedlander, N. Colombo, P. Harter, K. Fujiwara, I. Ray-Coquard, S. Banerjee, J. Liu, E.S. Lowe, R. Bloomfield, P. Pautier, J. Korach, T. Huzarski, T. Byrski, P. Pautier, P. Harter, N. Colombo, S. Pignata, G. Scambia, M. Nicoletto, F. Nussey, A. Clamp, R. Penson, A. Oza, A. Poveda Velasco, M. Rodrigues, J.P. Lotz, F. Selle, I. Ray-Coquard, D. Provencher, A. Prat Aparicio, L. Vidal Boixader, C. Scott, K. Tamura, M. Yunokawa, A. Lisyanskaya, J. Medioni, N. P\u00e9cuchet, C. Dubot, T. de la Motte Rouge, M.C. Kaminsky, B. Weber, A. Lortholary, C. Parkinson, J. Ledermann, S. Williams, S. Banerjee, J. Cosin, J. Hoffman, R. Penson, M. Plante, A. Covens, G. Sonke, F. Joly, A. Floquet, S. Banerjee, H. Hirte, A. Amit, T.W. Park-Simon, K. Matsumoto, S. Tjulandin, J.H. Kim, L. Gladieff, R. Sabbatini, D. O'Malley, P. Timmins, D. Kredentser, N. La\u00ednez Milagro, M.P. Barretina Ginesta, A. Tibau Martorell, A. G\u00f3mez de Lia\u00f1o Lista, B. Ojeda Gonz\u00e1lez, L. Mileshkin, M. Mandai, I. Boere, P. Ottevanger, J.H. Nam, E. Filho, S. Hamizi, F. Cognetti, D. Warshal, E. Dickson-Michelson, S. Kamelle, N. McKenzie, G. Rodriguez, D. Armstrong, E. Chalas, P. Celano, K. Behbakht, S. Davidson, S. Welch, L. Helpman, A. Fishman, I. Bruchim, M. Sikorska, A. S\u0142owi\u0144ska, W. Rogowski, M. Bidzi\u0144ski, B. \u015apiewankiewicz, A. Casado Herraez, C. Mendiola Fern\u00e1ndez, M. Gropp-Meier, T. Saito, K. Takehara, T. Enomoto, H. Watari, C.H. Choi, B.G. Kim, J.W. Kim, R. Hegg, I. Vergote, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol. (2017). doi:https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2.","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0040","article-title":"[19 OS]Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","author":"Oza","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0055","doi-asserted-by":"crossref","DOI":"10.1080\/14737167.2018.1464394","article-title":"An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study","author":"Lazzaro","year":"2018","journal-title":"Expert Rev. Pharmacoeconomics Outcomes Res."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-019-00909-6","article-title":"Maximum tolerated dose and pharmacokinetics of paclitaxel micellar in patients with recurrent malignant solid tumours: a dose-escalation study","author":"Borg\u00e5","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0065","series-title":"Common Terminology Criteria for Adverse Events v3.0","first-page":"0","author":"Cancer Therapy Evaluation Program","year":"2006"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0075","series-title":"EQ-5D-5L User Guide","author":"Janssen","year":"2015"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0080","series-title":"EORTC Quality of Life Group Manuel for the Use of EORTC Measures in Daily Clinical Practice","author":"Wintner","year":"2016"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Patients with stage iii and stage iv ovarian cancer","volume":"334","author":"Mc Guire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0090","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","author":"Piccart","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0095","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2014.14","article-title":"Model-based meta-analysis for quantifying paclitaxel dose response in cancer patients","volume":"3","author":"Lu","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2011.115","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment","author":"Pachman","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-014-2607-5","article-title":"Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer","author":"Rivera","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342","author":"Winer","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0120","doi-asserted-by":"crossref","unstructured":"H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, <Gelderblom2001EuJCancer.pdf>, 37 (2001) 1590\u20131598.","DOI":"10.1016\/S0959-8049(01)00171-X"},{"key":"10.1016\/j.ygyno.2019.11.034_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario) study","author":"Gonz\u00e1lez-Mart\u00edn","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.034_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","author":"Ledermann","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:46:59Z","timestamp":1758772019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819316853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0090825819316853"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}